Table 2.
Annual RHNF incidence and management among the Humana population between 2007 and 2014.
Year | RHNF | RHA | % Use of RHA | ORIF | % Use of ORIF | Non-op Tx | % Use of Non-op Tx |
---|---|---|---|---|---|---|---|
2007 | 1,773 | 77 | 4.34% | 545 | 30.74% | 550 | 31.02% |
2008 | 2,020 | 88 | 4.36% | 584 | 28.91% | 574 | 28.42% |
2009 | 2,122 | 102 | 4.81% | 676 | 31.86% | 673 | 31.72% |
2010 | 2,319 | 93 | 4.01% | 671 | 28.93% | 684 | 29.50% |
2011 | 2,462 | 129 | 5.24% | 704 | 28.59% | 737 | 29.94% |
2012 | 2,631 | 141 | 5.36% | 723 | 27.48% | 771 | 29.30% |
2013 | 3,156 | 182 | 5.77% | 785 | 24.87% | 885 | 28.04% |
2014 | 3,917 | 216 | 5.51% | 924 | 23.59% | 1,013 | 25.86% |
Totals | 20,400 | 1,028 | 5,612 | 5,887 | |||
Trend p-value |
<0.001 | <0.001 | 0.011 | <0.001 | 0.004 | <0.001 | 0.046 |